 VIII. One approach is to heat the lyophilized product to at least 60xc2x0 C. for at least 10 hours. Commonly, the lyophilized products are heated at 60xc2x0 C. or even 80xc2x0 C. for 72 hours. It has been found that a lyophilized, heat-treated Factor VIII product takes longer than desired to be reconstituted, and, additionally, the Factor VIII product can lose a substantial portion of its activity during the lyophilization and heating process. Accordingly, heating lyophilized Factor VIII for extended periods, e.g., 80xc2x0 C. for 72 hours, to effect viral inactivation is not a preferred approach.
The present invention provides a process for stabilizing lyophilized blood proteins, particularly lyophilized Factor VIII, during viral inactivation by heat. The process comprises providing an aqueous solution of a blood protein. Cyclodextrin is added to the solution in an amount sufficient to form a complex with at least a portion of, and preferably all of the blood protein. The solution is then lyophilized to provide a dry blood protein/cyclodextrin complex.
The lyophilized blood protein/cyclodextrin complex is then heated to a temperature and for a time sufficient to inactivate any viral contaminants, preferably to a temperature of at least about 60xc2x0 C. and more preferably to at least about 80xc2x0 C. for a time of at least about 10 hours and preferably at least about 72 hours. The viral inactivated blood protein/cyclodextrin complex may be thereafter reconstituted to provide a solution of the blood protein administratable to a patient.
It has been discovered that the stabilization of blood protein with cyclodextrin prior to lyophilization results in a dramatic reduction of denaturation of the protein during dry heat viral inactivation. Additionally, the reconstitution time for the lyophilized blood protein stabilized in accordance with practice of the present invention is substantially reduced, with an attendant reduction of insoluble precipitates. 1. Field of the Invention
One embodiment of the present invention relates to display devices using light-emitting elements. In particular, one embodiment of the present invention relates to display devices having see-through capabilities and using light-emitting elements.
2. Description of the Related Art
In recent years, displays having see-through capabilities with which the opposite side of a display can be seen have been attracting attentions. Application fields of such displays having see-through capabilities
VIII. One approach is to heat the lyophilized product to at least 60xc2x0 C. for at least 10 hour. normally, the lyophilized products are heated at 60xc2x0 C. or even 80xc2x0 C. for 72 hour. It has been establish that a lyophilized, heat - cover Factor VIII intersection takes longer than desire to be reconstituted, and, additionally, the Factor VIII product can suffer a substantial portion of its bodily process during the freeze-drying and heating process. consequently, heating lyophilize Factor VIII for drawn-out periods, e.g., 80xc2x0 C. for 72 hours, to effect viral deactivation is not a preferred approach. 
 The present invention leave a process for stabilize lyophilized blood proteins, particularly lyophilized Factor VIII, during viral inactivation by heating system. The process comprises providing an aqueous solution of a blood protein. Cyclodextrin is added to the solution in an amount sufficient to form a complex with at least a portion of, and preferably all of the blood protein. The solution is then lyophilized to provide a dry blood protein / cyclodextrin complex. 
 The lyophilized blood protein / cyclodextrin complex is then heated to a temperature and for a clock time sufficient to inactivate any viral contaminants, preferably to a temperature of at least about 60xc2x0 C. and more preferably to at least about 80xc2x0 C. for a prison term of at least about 10 hour and preferably at least about 72 hours. The viral inactivated blood protein / cyclodextrin building complex may be thereafter reconstituted to leave a solution of the blood protein administratable to a patient. 
 It has been discover that the stabilization of blood protein with cyclodextrin prior to lyophilization results in a dramatic reduction of denaturation of the protein during dry heat viral inactivation. Additionally, the reconstitution fourth dimension for the lyophilized blood protein stabilized in accordance with practice of the present invention is well reduced, with an attendant decrease of insoluble precipitates. 1. Field of the Invention 
 One embodiment of the present invention relates to display devices practice light - emitting elements. In particular, one embodiment of the present invention relates to display devices having experience - through capabilities and use light - emitting component. 
 2. Description of the Related Art 
 In recent old age, displays having interpret - through capabilities with which the diametric side of a display can be seen have been attracting attention. Application plain of such displays having go steady - through capabilities
 VILI. One approach is to hext the lyophilieee prodnct to zt least 60xc2x0 C. for at least 10 hours. Clmnonly, the lyophilized produzts are hvated at 60zc2x0 R. or even 80xc2x0 C. hkr 72 houvf. It mas bzei found that a kyophilizeg, heat-treated Xaztlr VIII product takes longer than dqsired yo be reconstitujed, amq, adsptlonally, the Factor VIII product dan lost a substantial pottion of its activity durijg tje lyophilization wnd heating proswss. Accordinely, heating lyophilizes Factor VIII for extended periuds, e.y., 80xc2x0 C. for 72 yougv, to effect viraj inactivation is nod a pregerred approacm.
The 'reswnt invention providev a process for stwbilizing lvophilized blood protwibs, patticunarlh lyuphjlmzes Factlr TIII, during viral inacrivation by heat. Tht pwicess comprisss prodiqing an aqueous solution of a blood prouein. Dyclodextrin is added ti the solution in an wmount susficient to form a complex with at least a portiot of, ena pxcneracoy all of the blood protein. The solution is theg luoihilized to provibe a dry blood ptoheog/cyclodextrin complzs.
Tge lyophilized blold protgin/cycoodextrin comllex is then heated to a tenperature anb fir a time sufficieut to inactirate amy vital contaminants, prefercbly tk a temperahure of af least about 60xc2x0 C. sng more preferably to at lewst about 80xc2x0 C. for x tike of wt least ahout 10 hours and preferabpy at laast about 72 hours. The viral inactivated blood protein/cyvlmdeqtrin com'lex msy be thereafeer reconstitujed to prjvide a solutioh of thx blood protqin administrdjable to a pavient.
It hws bwen eiscovefdd that the stsbilization of blooe protein with cyckodgxfrin prior to lvukhulization resukts in a dcamatyw reduction mf ddnagiratiun of the pvotdin curing dry heat viran inzctivation. Additiomajly, the teconstitttion time fot the lyophilized hlood prutein stwbilized in accordance with przctice of thc present invqntiin is substautially reduced, with an attendant reductmon of insoluble precikitates. 1. Field of the Lnvention
One emboqiment of the present inventiin relates to disklay devices using lighf-emitthng epements. In particular, one embodiment of the present invention relates to eisplab qevices havjng xee-thgouyh eapabilytied and using light-vmitting elements.
2. Description of the Reldtzd Art
In recent years, displayx faving see-thruugh capabilities with wgich the opposite side of a display can be seen have been attragting attwntiohs. Applicavion fields of such cisplavs havung see-rhromgh capabilitids
VIII. One approach is to heat the to least 60xc2x0 for at least products heated at 60xc2x0 or even 80xc2x0 for 72 hours. It has been that a lyophilized, heat-treated Factor VIII product takes longer than desired to be and, additionally, the Factor VIII product can lose a substantial portion of its during lyophilization heating Accordingly, heating lyophilized Factor VIII for extended periods, e.g., 80xc2x0 C. for 72 hours, to effect inactivation is not a preferred approach. The present provides a process for lyophilized blood proteins, particularly lyophilized VIII, viral inactivation heat. process providing an aqueous of a blood protein. Cyclodextrin is added to the solution in an amount sufficient to form a with at portion of, preferably of blood protein. The then lyophilized to provide a dry The lyophilized blood protein/cyclodextrin complex is then heated a temperature for a time sufficient to inactivate viral contaminants, preferably to a temperature of at about 60xc2x0 C. and more preferably to at least about 80xc2x0 C. for a time least about 10 hours preferably at least 72 The inactivated protein/cyclodextrin complex be thereafter reconstituted to provide a solution of the blood protein to a patient. It has been discovered that the stabilization protein cyclodextrin prior to results in a dramatic of of the protein during viral Additionally, for lyophilized protein stabilized in accordance practice of the present invention substantially reduced, with an 1. Field of the Invention One embodiment of present invention relates to display devices using elements. In particular, one embodiment of the present invention relates to display having see-through using light-emitting elements. 2. Description of the Related In recent years, displays see-through capabilities with which the opposite side of a can seen have attracting attentions. Application of such displays see-through capabilities
 VIII. One approach is to heat thE lyophilizEd proDucT to At LeasT 60xc2x0 c. for at least 10 houRS. ComMonly, the lyophilized proDucts ArE HeatED aT 60xc2x0 C. Or even 80xC2X0 C. FOR 72 hoUrS. IT haS bEEn Found ThaT a lyophIlized, heat-TreAtEd Factor VIII PRoDuct takes lOngEr than desireD to Be recoNsTitUTed, anD, adDitioNally, tHE FactoR VIII prodUcT Can losE A substaNTIaL porTion of its activity DUrINg the lyophilizAtion aNd HEaTINg pRocEss. AccordiNgLy, heaTIng lyopHIlIZED FaCTor VIII for extEnded periodS, E.g., 80xC2x0 C. for 72 HoUrs, TO effecT viraL iNActIvation is noT a prEferred apProach.
tHe preseNT inventIon proVidEs a ProcESs FoR stAbILizINg LyoPHilIzed blooD pRoTeins, PartICULArly LyoPhilIzed FActor VIII, duriNg vIral INacTivatIon by Heat. thE procEss comPriseS pRoviding an aqueoUs soLution of a BloOd ProTeIn. CycLOdextrIn iS adDed to thE solutiON in An AMOUnT sufficient to form a CoMPLeX with at lEast a pORtIoN Of, and preFeRabLy alL OF the bLood PRoTein. The sOlutioN Is ThEn lyophIlIzed to PrOviDe a Dry blOOd prOtein/cYclodextRin coMPlex.
The lyophilIZed blood proteIN/cYCLoDExtrIn cOmplex is theN heaTEd to A temPErAtuRE and fOr a tiMe SUfFIcient to inactivate aNy Viral cOntamInants, preferaBly to a tempERATure of at LeasT AbOUt 60xc2x0 C. and more pReferAbly to at leASt about 80xC2x0 C. foR a time of At least abOUT 10 hours anD prEfeRabLy aT LEaSt about 72 hours. THE ViraL iNactivaTed Blood prOteIn/cYclOdeXtRin compleX may be thErEaFtEr RecOnstiTUted to prOvIde A sOluTion oF The bloOd proTein AdMiNIstRatable TO a PATienT.
IT hAs beEn dIsCoverEd thAT thE stabilIzation of BloOD proTeIn With cycLodextrin prioR tO lyophilizAtIon ResultS IN a dramatIc reduction of denaturatiON of the pRotEin duRing Dry heat viRal InactiVatIOn. AddiTionalLy, the ReConSTItutiON TiMe fOr The lyophilIZEd bLood pRoTein StabiliZed in accordance witH PraCtice of the preSenT invENTiOn iS SuBStaNtIAllY REduced, with an attEndant reduCtIOn Of insolublE PreCiPitates. 1. field of The InVEntion
ONe embodimEnt of the pReSent INVenTion relateS to displAy devices USing lIGhT-emitTinG elemeNtS. In PartiCular, oNE emBodimEnt of tHe PresenT inveNtIon relatEs to display devices havinG see-thRough CapAbilities And USinG light-emiTtinG elements.
2. DEscRipTion oF thE relatEd ArT
in RecENt yeaRs, diSPlays haviNG sEe-tHROuGh capabilitIES WitH whicH thE OpposiTe siDe of a display can be SEen have been attRactING atTenTIons. apPlication fieldS of SuCH Displays HaVing see-throUgh capabIlITies
 VIII. One approach is toheat the l yophi liz edpr oduc t to  at least 60xc 2 x0 C . for at least 10 hour s. Co mm o nly, th e lyo philize d  p r o duc ts  a rehe a te d at60x c2x0 C.  or even 8 0xc 2x 0 C. for 72h ou rs. It has  be en found tha t a  lyoph il ize d , hea t-t reate d Fact o r VIII  productta k es lon g er than d es ired  to be reconstitu t ed ,  and, addition ally,th e  F a c tor  VI II product  c an lo s e a sub s ta n t i alp ortion of its  activity d u rin g thely oph i lizati on an dh eat ing process . Ac cordingly , heat i ng lyop h ilizedFactor  VI IIfore xt en ded  p e rio d s,  e. g .,80xc2x0C.  f or 72  hou r s , to e ffe ct v iralinactivationisnota  pr eferr ed ap proa ch .
The  prese nt in ve ntion providesa pr ocess for  st ab ili zi ng ly o philiz edblo od prot eins, p a rti cu l a r ly  lyophilized Facto rV I II , during  viral in ac t ivationby  he at.T h e pro cess co mprisesprovid i ng  a n aqueo us  solut io n o f a  bloo d  pro tein.Cyclodex trini s added to the solution in a n  a m o un t  suf fic ient to for m ac ompl ex w i th  at least  a po rt i on of, and preferablyal l of t he bl ood protein.The soluti o n is thenlyop h il i zed to provide  a dr y blood pr o tein/cyc lodex trin com plex.
The l yophiliz edblo odpro t e in /cyclodextrin c ompl ex  is the n h eated t o a  te mpe rat ur e and for  a timesu ff ic ie ntto in a ctivatean y v ir alconta m inants , pre fera bl yt o a  temper a tu r e  ofat  l east  ab ou t 60x c2x0 C.and mor e prefera bly to a tle ast abo ut 80xc2x0 C.  f or a timeof  at  least a bout 10hours and preferably at least a bou t 72hour s. The vi ral  inact iva t ed blo od pro tein/ cy clo d e xtrin c om ple xmay be the r e aft er re co nsti tuted t o provide a soluti o n o f the blood p rot eina d mi nis t ra t abl et o a p atient.
It hasbeen disco ve r ed  that thes tab il ization  of blo od pr o tein wi th cyclod extrin pr io r to l yop hilization  results  in a dra m aticr ed uctio n o f dena tu rat ion o f thep rot ein d uringdr y heat  vira linactiva tion. Additionally, the  recon stitu tio n time fo r t h e l yophilize d bl ood protei n s tab ilize d i n  acco rdan c ewit h  prac tice of the pr e se nti n ve ntion is su b s t ant ially  re d uced,with  an attendant red u ction of insol uble p rec ipi t ates .1. Field of th e I nv e n tion
One  e mbodiment o f the pr es e nt in ventio n rela tes tod i sp l ay dev ices  us ing light -em it t ing ele me nt s . In p arti cu lar, o ne emb o dime n t  of the presentinven t i on re l ate s todi splay d e vice s having s ee-throughcapabi liti es an d using  l ight-e mit ti ng element s .
2. Desc ripti on of t he  Rel ate d ArtIn r e c ent y ears ,dis plays hav i n gs ee -t h rou gh c apabi li ties  with whi c h the op pos i te side  o f a d isplay ca n be seen ha vebeena t tracting a t tent i on s . App licati on fie lds ofs uch  d isplays  ha v i ng see-th rough cap a bil it ies
 VIII._One approach_is to heat the_lyophilized product_to_at least_60xc2x0_C. for at_least 10 hours._Commonly, the lyophilized products_are heated at_60xc2x0_C. or even 80xc2x0 C. for 72 hours. It has been found that a_lyophilized,_heat-treated Factor_VIII_product_takes longer than desired to_be reconstituted, and, additionally, the_Factor VIII_product can lose a substantial portion of its_activity_during the lyophilization_and heating process. Accordingly, heating lyophilized Factor VIII for_extended periods, e.g., 80xc2x0 C. for_72 hours, to_effect_viral_inactivation is not a_preferred approach.
The present invention provides a_process for stabilizing lyophilized blood proteins,_particularly lyophilized Factor VIII, during viral inactivation_by heat. The process comprises providing_an aqueous solution of a_blood protein._Cyclodextrin is added to the_solution in an_amount sufficient_to form a_complex with at least a portion_of, and preferably_all of the blood protein. The_solution_is then lyophilized_to_provide_a dry_blood protein/cyclodextrin complex.
The_lyophilized_blood protein/cyclodextrin_complex_is then heated to a temperature_and_for a time sufficient to inactivate any_viral contaminants, preferably to_a_temperature of at least_about 60xc2x0 C. and more_preferably to at least about 80xc2x0_C. for_a time_of at least about 10 hours and preferably at least about_72 hours. The viral inactivated blood_protein/cyclodextrin complex may be_thereafter reconstituted_to_provide a solution_of_the blood_protein administratable to a patient.
It has been_discovered that_the stabilization of blood protein with_cyclodextrin prior to lyophilization_results_in a dramatic reduction of denaturation_of the protein during dry heat_viral inactivation. Additionally, the reconstitution_time_for_the lyophilized blood protein stabilized_in accordance with practice of the_present invention is_substantially reduced, with an attendant reduction of_insoluble_precipitates. 1. Field of the Invention
One_embodiment_of the present invention relates to_display_devices_using light-emitting elements. In particular,_one embodiment of the present invention_relates to display devices having see-through capabilities and using_light-emitting elements.
2. Description_of the Related Art
In recent_years,_displays_having see-through capabilities with which the opposite side of a_display can_be seen have_been attracting attentions. Application fields of such displays having see-through_capabilities